Media
Large drugmakers are developing fewer antibiotics, analysis finds
10 March 2026
Date
10 March 2026
Bright spots in tackling AMR, but drug-resistance outpaces pharma industry efforts
In an article for The Hindu Business Line, PT Jyothi Datta covers the release of the 2026 Antimicrobial Resistance (AMR) Benchmark, highlighting the report’s key finding that more effort must be allocated to developing antimicrobial products for children.
Direct links
The article highlights a key theme from the report: that investment by large, research-based pharmaceutical companies in the AMR space has significantly declined over the five-year period since the 2021 AMR Benchmark.
It also draws out notable bright spots in company behaviour from the report, including Aurobindo, GSK, Hikma, Sandoz and Teva’s efforts in registering child-friendly formulations more widely than peers. It also notes that these efforts are lagging in low- and middle-income countries, especially in Africa.
Highlighting the actionability of the report, it quotes Jayasree K. Iyer, CEO of the Access to Medicine Foundation: “Our findings show practical approaches that can ramp up progress on all fronts.”
